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Abstract
Background: C-reactive protein (CRP), a biomarker of inflammation, has been associated with increased risk of
developing cardiovascular disease. Common variants of the hepatocyte nuclear factor 1A (HNF1A) gene encoding
HNF-1a have been associated with plasma CRP in predominantly European Caucasian samples. HNF1A might
therefore have an impact on vascular disease and diabetes risk that is mediated by CRP. In an Aboriginal Canadian
population, a private polymorphism, HNF1A G319S, was associated with increased prevalence of type 2 diabetes.
However, it has not been investigated whether this association is mediated by CRP. We aimed to investigate
whether CRP was mediating the association between HNF1A G319S and type 2 diabetes in an Aboriginal Canadian
population with a high prevalence of diabetes.
Methods: A total of 718 individuals who participated in a diabetes prevalence and risk factor survey were included
in the current analysis. Participants were genotyped for HNF1A G319S. Fasting plasma samples were analyzed for
CRP. Fasting plasma glucose and a 75-g oral glucose tolerance test were obtained to determine type 2 diabetes.
Results: The prevalence rate of type 2 diabetes was 17.4% (125/718) using the 1999 World Health Organization
definition and was higher among S319 allele carriers compared to G/G homozygotes (p < 0.0001). Among
participants without type 2 diabetes, CRP levels were higher among G/G homozygotes (1.64 [95% confidence
interval 1.35-2.00] mg/l) than in S319 carriers (1.26 [1.04-1.54] mg/l) (p = 0.009) after adjustment for age, sex, 2-h
post-load glucose, waist circumference, and serum amyloid A. CRP levels were elevated among those with diabetes
after similar adjustment (4.39 [95% confidence interval 3.09-6.23] and 4.44 [3.13-6.30] mg/L, respectively), and no
significant difference in CRP was observed between S319 carriers and non-carriers (p = 0.95).
Conclusions: CRP levels were lower in S319 allele carriers of the HNF1A gene compared to non-carriers among
individuals without diabetes, but this difference was not present among those with diabetes, who uniformly had
elevated CRP levels. Therefore, while HNF1A appears to influence CRP concentrations in the non-diabetic state,
chronic elevation of CRP is unlikely mediating the association between the HNF1A polymorphism and the high
prevalence of type 2 diabetes in this Aboriginal population.
Background
C-reactive protein (CRP), a biomarker of inflammation,
has been associated with increased risk of developing
cardiovascular disease [1,2]. In addition, plasma CRP
concentrations have been associated with polymorph-
isms in the hepatocyte nuclear factor 1A (HNF1A) [3-5].
In a recent genome-wide association study, several loci
including HNF1A which are involved in protein produc-
tion related to insulin resistance, beta-cell function,
weight gain, diabetes and/or early atherogenesis were
associated with plasma CRP [4]. Based on these findings,
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HNF1A may have subsequent impact on vascular disease
and diabetes influenced or marked by circulating CRP
concentrations. In another genome-wide study, however,
the authors reported that the HNF1A locus was not
associated with coronary heart disease (CHD), although
the locus was associated with CRP levels [5].
The HNF1A gene codes for a transcription factor,
HNF-1a, which plays an important role in pancreatic
beta-cell function [6-8]. In various populations, poly-
morphisms in the HNF1A gene are a common cause of
maturity-onset diabetes of the young (MODY) [7-10],
which is characterized by early age of onset and a
marked defect in insulin secretion. CRP concentrations
in MODY3 patients with severe loss-of-function muta-
tions in HNF1A have not been systematically reported.
In an Aboriginal Canadian population, a glycine to ser-
ine substitution at codon 319 (G319S) of the HNF1A
gene was observed [11]. Unlike typical HNF1A variants
in MODY3, the diabetes phenotype that emerged in this
private polymorphism was non-MODY type 2 diabetes
[11,12], although the S319 allele was associated with
accelerated onset of type 2 diabetes in a gene-dosage
manner in this population [12].
The recent genome-wide studies reported that varia-
tion in the HNF1A locus was associated with CRP con-
centrations [3-5], but not with CHD [5], suggesting that
HNF1A is unlikely involved in CHD pathogenesis
mediated by CRP. However, it has not been investigated
whether plasma CRP mediates the association between
the HNF1A polymorphism and type 2 diabetes. The aim
of this study therefore was to determine whether CRP
was mediating the association between HNF1A G319S
and type 2 diabetes in an Aboriginal Canadian commu-
nity known to have a high prevalence of type 2 diabetes
[13].
Methods
The Sandy Lake Health and Diabetes Project is a popu-
lation-based study designed to determine diabetes rates
and associated risk factors in an Aboriginal Canadian
population. Between 1993 and 1995, data were obtained
from 728 of 1018 (72%) eligible residents of Sandy Lake
First Nation aged 10-79 years [13]. Signed and informed
consent was obtained from all participants, and the
study was approved by the Sandy Lake First Nation
Band Council and University of Toronto Ethics Review
Committee. After excluding participants with missing
variables, 718 remained in the current analysis.
Data collection and laboratory procedures
Blood samples were collected after an 8- to 12-h over-
night fast to determine fasting glucose, insulin, lipid
profile, CRP, and serum amyloid A (SAA) [13,14].
A 75-g oral glucose tolerance test was administered, and
a second blood sample for glucose was drawn at 120 min-
utes post-load. Glucose concentration was determined
using the glucose oxidase method. Insulin concentration
was analyzed by radioimmunoassay (Pharmacia, Piscat-
away, NJ). Triglyceride, high-density lipoprotein (HDL)
cholesterol and low-density lipoprotein (LDL) cholesterol
were determined using standard methods described in
the Lipid Research Clinics manual of operations [15].
CRP concentration was assessed using the Behring BN
100 and the N high-sensitivity CRP reagent (interassay
CV 5.0% at 12.8 mg/l) (Dade-Behring, Mississauga, ON).
SAA was determined using an enzyme-linked immuno-
sorbent assay (interassay CV 11% at 81 mg/l) (BioSource
International, Camarillo, CA). The homeostasis model
assessment (HOMA) of insulin resistance (IR) and beta-
cell function (beta) were estimated by the method of
Matthews et al. [16]. Type 2 diabetes was defined by the
revised 1999 World Health Organization (WHO) diag-
nostic criteria of fasting plasma glucose ≥7.0 mmol/l or
2-h postload plasma glucose ≥11.1 mmol/l.
Each anthropometric and blood pressure determina-
tion was performed twice, and the average was used in
analyses. Waist circumference was measured at the iliac
crest using an inelastic tape. Interviewers administered
questionnaires to obtain demographic information.
Genetic analysis
Restriction analysis with BseDI followed by polyacryla-
mide gel electrophoresis was used to detect the DNA
change underlying the HNF1A G319S amino acid var-
iant [11]. DNA sequence-proven controls were run as
standards for each genotyping reaction and a random
15% of samples were studied on another day with inde-
pendent genotyping reactions. The concordance
between replicates was 100%.
Statistical analysis
Distributions of continuous variables were assessed for
normality, and natural log transformations of skewed
variables including CRP were used in statistical analyses.
Descriptive statistics for continuous variables were sum-
marized as mean ± standard deviation or median (25
th-
75
th percentile) for variables with a skewed distribution.
Categorical variables were summarized using propor-
tions. Characteristics of S319 allele carriers and non-car-
riers were compared using Welch’s modified t test or
chi-square test as appropriate. Fisher’se x a c tt e s tw a s
used to assess HNF1A genotype frequencies. S/S319 and
S/G319 genotypes were combined in subsequent ana-
lyses due to a small number of S/S319 carriers (n = 6)
in the study population. For the purpose of analysis and
discussion, individuals with S/S and S/G genotypes will
be referred to as “S319 carriers”.
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morphism with log CRP, least square means were calcu-
lated using general linear models: model 1, unadjusted;
model 2, adjusted for age, sex, and log 2-h post-load
glucose; model 3, adjusted for model 2 variables in addi-
tion to waist circumference; model 4, adjusted for
model 3 variables and log SAA. Log SAA was added in
the model 4 to assess whether the association between
HNF1A and CRP was independent of another inflamma-
tory marker.
The sex interaction with HNF1A G319S on log CRP
levels was assessed by adding an interaction term to a
model that included the G319S polymorphism with
adjustment for age, sex, log 2-h post-load glucose, waist
circumference, and log SAA. Data analyses were per-
formed with the use of SAS software, version 9.2 (SAS
Institute, Cary, NC), and with the consideration of two-
sided p < 0.05 as statistically significant for all analyses.
Results
Characteristics of study participants are presented in
table 1 according to the HNF1A G319S carrier status.
There were no statistically significant differences
between S319 allele carriers and non-carriers in meta-
bolic risk variables, except for fasting and 2-hr post-load
glucose levels and HOMA-beta (p < 0.05) (table 1).
The prevalence rate of type 2 diabetes was 17.4% (125/
718) using the 1999 WHO definition and was higher
among S319 allele carriers compared to non-carriers
(p < 0.0001) (table 2). Individuals with diabetes were
older and more likely to have hypertension and they
had lower HDL cholesterol and HOMA-beta and higher
adiposity measures, LDL cholesterol, triglyceride, fasting
and 2-h postload glucose, HOMA-IR, CRP, and SAA
(all < 0.001; see additional file 1: table S1-characteristics
of participants according to the diabetes status).
In individuals without type 2d i a b e t e s ,C R Pl e v e l so f
S319 carriers and non-carriers were compared (table 3).
In the unadjusted model, CRP was higher among S319
non-carriers compared to carriers (p = 0.02). After
adjusting for age, sex, log 2-h post-load glucose, waist
circumference, and log SAA, least square mean CRP
levels remained higher among S319 non-carriers (1.64
[95% confidence interval 1.35-2.00] mg/l) than in S319
carriers (1.26 [1.04-1.54] mg/l) (p = 0.009) (table 3).
Additionally adjusting the model 4 for HDL cholesterol,
LDL cholesterol, hypertension, triglyceride, smoking his-
tory, HOMA-IR, or HOMA-beta did not change this
association (beta effect size change ≤3% for each model)
(data not shown).
Among individuals with type 2 diabetes, CRP levels
were not significantly different between S319 non-car-
riers and carriers when adjusted for age, sex, log 2-h
post-load glucose, waist circumference, and log SAA
(4.44 [95% CI 3.13-6.30] and 4.39 [3.09-6.23] mg/L,
respectively; p = 0.95) (all other models p > 0.05; table 4).
Table 1 Characteristics of participants according to the HNF1A G319S carrier status
Characteristic G/G319 S/G + S/S319 p
n (%) 554 (78.6) 151 (21.4)
Age (years)* 30.0 ± 15.9 30.6 ± 15.4 0.70
Sex, male† 220 (39.7) 76 (50.3) 0.02
BMI (kg/m
2)* 26.6 ± 5.90 27.0 ± 5.22 0.52
Waist circumference (cm)* 97.6 ± 14.7 99.1 ± 13.2 0.24
Hypertension, yes†‡ 119 (21.5) 30 (19.9) 0.67
HDL cholesterol (mmol/l)* 1.25 ± 0.28 1.23 ± 0.27 0.46
LDL cholesterol (mmol/l)* 2.59 ± 0.74 2.56 ± 0.79 0.75
Triglyceride (mmol/l) § 1.25 (0.88-1.71) 1.27 (0.97-1.87) 0.06
Fasting glucose (mmol/l) § 5.4 (5.1-5.9) 5.6 (5.0-7.6) < 0.0001
2-hour postload glucose (mmol/l) § 5.7 (4.4-7.2) 6.0 (4.8-9.8) 0.002
HOMA-insulin resistance§ 3.61 (2.38-6.27) 3.96 (2.16-6.87) 0.44
HOMA-beta§ 144.4 (98.3-204.5) 110.3 (67.8-180.5) 0.0004
C-reactive protein (mg/l) § 2.17 (0.63-5.73) 1.85 (0.57-5.05) 0.29
Serum amyloid A (mg/l) § 7.71 (4.73-12.98) 7.18 (5.03-11.39) 0.48
Abbreviation: BMI, body mass index; HDL high-density lipoprotein; LDL low-density lipoprotein; HOMA, homoeostasis model assessment. N of subjects for each
characteristic varying slightly due to occasional missing values. *Mean ± standard deviation and Welch’s t test performed. †n (%) and Chi-Square test performed.
‡Hypertension is defined as a systolic blood pressure ≥130 mmHg or diastolic blood pressure of ≥85 mmHg or receiving antihypertensive medication therapy.
§Medians (25
th-75
th percentile) and Welch’s t test performed on log transformation.
Table 2 HNF1A genotype frequencies and prevalence of
type 2 diabetes using 1999 WHO definition
G/G319 S/G319 S/S319 p
Total, n (%) 554 (78.6) 145 (20.6) 6 (0.9) < 0.0001
Diabetes, n (%) 77 (13.9) 42 (29.0) 5 (83.3) <0.0001
Fisher’s exact test was performed.
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polymorphism on CRP levels (p > 0.05).
Discussion
In diabetes-free individuals, plasma CRP levels were
lower among the S319 allele carriers compared to non-
carriers, although both group mean CRP levels were
within the average risk range for cardiovascular events
(1.0-3.0 mg/L) [17]. Among individuals with type 2 dia-
betes, however, CRP levels were elevated to the high
risk range for cardiovascular events (> 3 mg/L) [17] in
both S319 allele carriers and non-carriers. In addition,
the difference in CRP levels between the S319 carrier
statuses was not present in those with diabetes, who are
likely under chronic inflammatory stress.
Genetic variations in the HNF1A gene encoding HNF-
1a protein have been associated with plasma CRP
concentrations in predominantly European Caucasian
samples [3-5]. In a genome-wide association study, sev-
eral loci including HNF1A which are involved in protein
production related to insulin resistance, beta-cell func-
tion, weight gain, diabetes and/or early atherogenesis
were associated with plasma CRP [4]. Therefore, the
authors argued that variation in genes including HNF1A
may have subsequent impact on vascular disease and
diabetes risk that is influenced or marked by circulating
CRP concentrations. In another genome-wide study,
however, it was reported that the HNF1A locus was not
associated with CHD although the locus was associated
with CRP levels [5], arguing against a causal association
of CRP with CHD.
Although the association of CRP with increased risk of
developing cardiovascular disease has been well docu-
mented [1,2,5], previous studies on the association of
CRP with incident type 2 diabetes have been less consis-
tent. Several studies associated increased baseline levels
of CRP [18,19]with incident type 2 diabetes, while others
reported no association, including a report from the cur-
rent study population [20-22]. We have previously
reported a higher prevalence of type 2 diabetes among
HNF1A S319 carriers compared to non-carriers in this
population [11], which is paradoxical in the context of
the current finding of S319 carriers having a low level of
CRP. The higher prevalence of type 2 diabetes observed
among S319 carriers is likely explained by the compro-
mised ability of these subjects to mount an adequate
insulin response, resulting in an earlier loss of glycemic
control [12].
HNF-1a protein binding to promoter regions of the
CRP gene, down stream of the IL-6 responsive site, is
known to be involved in synergistic trans-activation of
CRP promoter [23-25]. The HNF1A G319S genomic
sequence was recently reported to give rise to two
abnormal transcripts, with altered quantities of the nor-
mal splicing products and reduced total HNF1A tran-
script levels [26]. Therefore, under the acute-phase
signaling mechanism, abnormal HNF-1a produced by
S319 carriers may have an impact on CRP production
explaining the lower CRP level observed among non-
diabetic individuals with the HNF1A G319S polymorph-
ism. Among individuals with diabetes who are likely
under chronic inflammatory stress, however, another
mechanism may be modulating increased circulating
CRP. Stimulation of the CRP promoter caused by
increased circulating IL-6 and/or other signaling factors
involved may be responsible for the increase in CRP
levels in diabetic subjects [27], while the synergistic
effects of HNF-1a contributing to CRP expression
would be masked in this setting [23-25].
Since ethnic variation in polymorphisms within the
coding regions of HNFs has been reported in non-Eur-
opean populations [28-30], it was important to confirm
the association of the population-specific polymorphism,
HNF1A G319S, with CRP. The current study provides
evidence that variation in HNF1A is associated with var-
iation in CRP in diabetes-free individuals (although not
Table 4 Concentrations of CRP according to the HNF1A
carrier status among participants with diabetes
Beta SE CRP [95% CI] (mg/L)* p
G/G319 S/G + S/S319
Model 1† -0.2162 0.1847 4.79 (3.33-6.88) 3.86 (2.69-5.54) 0.24
Model 2‡ -0.3514 0.2354 5.05 (3.18-8.01) 3.52 (2.22-5.58) 0.13
Model 3§ -0.2971 0.2286 4.96 (3.17-7.77) 3.69 (2.36-5.77) 0.20
Model 4∥ -0.0109 0.1786 4.44 (3.13-6.30) 4.39 (3.09-6.23) 0.95
*Least square mean CRP values are back-transformed after using log-
transformed CRP to calculate p-values. Group sample sizes of 77 (G/G319) and
47 (S/G + S/S319) have 99.9% power to detect a difference between mean
CRP concentrations ± standard deviations of 4.79 ± 1.03 (G/G319) and 3.86 ±
0.93 (S/G + S/S319) at a significance level of 0.05. †Model 1: unadjusted
‡Model 2: adjusted for age, sex, log 2-h post-load glucose §Model 3: adjusted
for model 2 variable and waist circumference ∥Model 4: adjusted for model 3
variables and log serum amyloid A
Table 3 Concentrations of CRP according to the HNF1A
G319S carrier status among participants without
diabetes
Beta SE CRP [95% CI] (mg/L) * p
G/G319 S/G + S/S319
Model 1† -0.3525 0.1498 1.65 (1.23-2.22) 1.16 (0.93-1.46) 0.02
Model 2‡ -0.2803 0.1351 1.65 (1.26-2.15) 1.24 (0.95-1.62) 0.04
Model 3§ -0.3310 0.1215 1.66 (1.31-2.11) 1.19 (0.94-1.51) 0.007
Model 4∥ -0.2635 0.1008 1.64 (1.35-2.00) 1.26 (1.04-1.54) 0.009
*Least square mean CRP values are back-transformed after using log-
transformed CRP to calculate p-values. Group sample sizes of 477 (G/G319)
and 104 (S/G + S/S319) have 90.8% power to detect a difference between
mean CRP concentrations ± standard deviations of 1.65 (G/G319) ± 1.39 and
1.16 (S/G + S/S319) ± 1.36 at a significance level of 0.05. †Model 1:
unadjusted ‡Model 2: adjusted for age, sex, log 2-h post-load glucose §Model
3: adjusted for model 2 variable and waist circumference ∥Model 4: adjusted
for model 3 variables and log serum amyloid A
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opean Caucasians.
Limitations
Our study was conducted within an isolated Aboriginal
community. Although this allowed us to investigate a
population-specific polymorphism, this also limited our
sample size. Therefore, it is recommended that our
study results be confirmed in future studies with larger
sample sizes, especially the observation in individuals
with diabetes. Furthermore, it would have been benefi-
cial to assess other biomarkers (e.g. HNF-1a protein) in
addition to CRP. Because our data collection was com-
pleted in 1993-1995 followed by biochemical assays, our
current data analysis was limited to previously assayed
biomarkers.
Conclusions
In summary, CRP levels were lower in HNF1A S319
allele carriers compared to non-carriers among Aborigi-
nal Canadians without diabetes, but this difference was
not present among those with prevalent type 2 diabetes,
a group with markedly elevated CRP levels. Therefore,
while HNF1A appears to influence CRP concentrations
in the non-diabetic state, chronic elevation of CRP is
unlikely mediating the association between the HNF1A
polymorphism and the high prevalence of 2 diabetes in
this Aboriginal population.
Additional material
Additional file 1: Table S1: Characteristics of participants according
to the diabetes status
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